Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity.
about
Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expressionRiluzole elevates GLT-1 activity and levels in striatal astrocytesRecent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS)Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?Mechanisms of glutamate transportGlutamate transporter 1: target for the treatment of alcohol dependenceCurrent approaches to enhance glutamate transporter function and expressionSLC transporters as therapeutic targets: emerging opportunitiesMethamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytesThe Concise Guide to PHARMACOLOGY 2013/14: transporters.Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotectionGlutamate as a neurotransmitter in the healthy brainGlutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics.Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's diseaseStructure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators.Phenotypic assays to identify agents that induce reactive gliosis: a counter-screen to prioritize compounds for preclinical animal studiesThe preclinical discovery of amyotrophic lateral sclerosis drugs.The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.Increased glial glutamate transporter EAAT2 expression reduces epileptogenic processes following pilocarpine-induced status epilepticus.HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS.De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies.Translational enhancers of EAAT2: therapeutic implications for neurodegenerative disease.Novel glutamatergic drugs for the treatment of mood disorders.Glutamate transporter activators as anti-nociceptive agentsGlutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.Brain endothelial cells induce astrocytic expression of the glutamate transporter GLT-1 by a Notch-dependent mechanism.Astroglia as a cellular target for neuroprotection and treatment of neuro-psychiatric disorders.EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis.Reactive Astrocytes as Drug Target in Alzheimer's Disease.Inhibition of p38 MAPK Signaling Regulates the Expression of EAAT2 in the Brains of Epileptic Rats
P2860
Q24595928-D136A12C-C480-4E05-AF37-2A3964330A55Q24610013-10B7F6FC-B2B6-41E5-9C5C-408DD0A9DB9BQ24613709-9550636D-BCFD-4DD3-AD7F-F98152B1BC30Q26770781-D4A8D7FF-207F-478A-9A81-E6F786988B7BQ26830761-A6810804-2F9E-41A6-BD2F-30B1068D4628Q26861666-149E6306-4B9A-4EF6-894E-280C24F12702Q26996723-01326795-249F-4242-8059-BDFFFA52D221Q27014726-AAE38565-7235-4B66-AC08-374AB855AD84Q28242470-5EB94E16-805F-4063-8DA3-77355FA94A45Q30486743-A5EA0FB6-F874-4DD0-AAA2-306D2DC7CB50Q30573062-216D5D83-9A3B-4E65-8D01-E3752C963F45Q34048502-FDE7B5BB-515B-48CE-B6E3-BC70C9BEBEE0Q34296136-4BDD87F6-B2BE-4960-AB29-B7ED60E03FA9Q35019375-59AE4975-9B05-4566-BEE0-F5B5F066A253Q35087565-E2629860-59E7-4D0D-8A42-67B95CCA5708Q35161465-D798D7A1-BEA8-40A1-B6C6-8D6FCF6AEF3BQ35212153-0344B428-2897-42DC-8BCB-165F0B22FB0CQ35729506-B6E68010-3DC2-4EAA-B8EB-80FF46098737Q36009915-CB2D3419-FEA9-4D1F-AD9D-4454B4B443DDQ36356318-00BCE017-73B4-4EF1-A07B-1B1992DC9AE7Q36610296-6A44771C-407D-49E9-A673-0F1D9912283BQ36634233-A535C2A0-F8A5-42AE-9DB2-679B1DDF4DB5Q37152969-0AA2527A-B434-485C-B4D4-A687D05B5C31Q37609642-A14C2CE3-1A4C-4184-81C7-859F2390E6BFQ38131480-C673CCAE-8748-476E-BBC7-D7924EF79F12Q38327802-F3007104-6A94-484C-AE75-8DE13295B080Q38512084-0430EA03-5280-4478-B4C2-8EAEAC34229DQ38695805-2F358154-5723-4B61-BD1C-8FA8AE1E018CQ39181656-5450E299-2D0B-4AE1-90AD-DE38E3EF945EQ51824569-5799D5C3-DB8E-48A2-8AFE-24DAFAA8BEDBQ55280382-3F7DD8E3-CCC6-40DD-B1A7-461EDC17F65EQ59138055-0D246D46-64A0-4A87-9759-51D6ACAC80DE
P2860
Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Identification of translationa ...... ach to prevent excitotoxicity.
@ast
Identification of translationa ...... ach to prevent excitotoxicity.
@en
Identification of translationa ...... ach to prevent excitotoxicity.
@nl
type
label
Identification of translationa ...... ach to prevent excitotoxicity.
@ast
Identification of translationa ...... ach to prevent excitotoxicity.
@en
Identification of translationa ...... ach to prevent excitotoxicity.
@nl
prefLabel
Identification of translationa ...... ach to prevent excitotoxicity.
@ast
Identification of translationa ...... ach to prevent excitotoxicity.
@en
Identification of translationa ...... ach to prevent excitotoxicity.
@nl
P2093
P2860
P356
P1476
Identification of translationa ...... ach to prevent excitotoxicity.
@en
P2093
Chien-Liang Glenn Lin
Craig K Colton
Gregory D Cuny
Kathleen I Seyb
Liching Lai
Marcie A Glicksman
Michael X Zhu
Qiongman Kong
P2860
P304
P356
10.1177/1087057110370998
P577
2010-05-27T00:00:00Z